trending Market Intelligence /marketintelligence/en/news-insights/trending/h2ame1pxhtlb84e_auhogg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Actinium to raise $32.5M via sale of common shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Actinium to raise $32.5M via sale of common shares

Actinium Pharmaceuticals Inc. will sell up to $32.5 million worth of its common shares to Lincoln Park Capital Fund LLC.

Lincoln Park plans to initially purchase 3,376,554 common shares priced at 74 cents apiece, for a total of $2.5 million in gross proceeds for the biotechnology company. Lincoln Park can then purchase additional shares up to $30 million in multiple installments over a period of 30 months. Upon entering the agreement, Actinium issued 852,537 common shares to Lincoln Park without any cash consideration.

Actinium, a New York-based developer of cancer therapies, plans to use the proceeds for general corporate purposes, general working capital and expanding its products.